Witten J, Samad T, Ribbeck K
Biomacromolecules. 2019; 20(4):1505-1513.
PMID: 30779551
PMC: 6581564.
DOI: 10.1021/acs.biomac.8b01467.
Schneider-Futschik E, Paulin O, Hoyer D, Roberts K, Ziogas J, Baker M
ACS Infect Dis. 2018; 4(5):646-655.
PMID: 29566483
PMC: 5952261.
DOI: 10.1021/acsinfecdis.7b00238.
Mensa J, Barberan J, Soriano A, Llinares P, Marco F, Canton R
Rev Esp Quimioter. 2018; 31(1):78-100.
PMID: 29480677
PMC: 6159363.
Dhand R
J Aerosol Med Pulm Drug Deliv. 2017; 31(3):121-138.
PMID: 29077527
PMC: 5994662.
DOI: 10.1089/jamp.2017.1415.
Ruddy J, Emerson J, Moss R, Genatossio A, McNamara S, Burns J
J Aerosol Med Pulm Drug Deliv. 2012; 26(2):69-75.
PMID: 22620494
PMC: 3621259.
DOI: 10.1089/jamp.2011.0942.
BqsR/BqsS constitute a two-component system that senses extracellular Fe(II) in Pseudomonas aeruginosa.
Kreamer N, Wilks J, Marlow J, Coleman M, Newman D
J Bacteriol. 2011; 194(5):1195-204.
PMID: 22194456
PMC: 3294787.
DOI: 10.1128/JB.05634-11.
Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.
Dartois V, Barry C
Curr Clin Pharmacol. 2010; 5(2):96-114.
PMID: 20156156
PMC: 6344931.
DOI: 10.2174/157488410791110797.
Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.
Sabet M, Miller C, Nolan T, Senekeo-Effenberger K, Dudley M, Griffith D
Antimicrob Agents Chemother. 2009; 53(9):3923-8.
PMID: 19528273
PMC: 2737871.
DOI: 10.1128/AAC.00268-09.
Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis.
Alipour M, Suntres Z, Halwani M, Azghani A, Omri A
PLoS One. 2009; 4(5):e5724.
PMID: 19479000
PMC: 2685033.
DOI: 10.1371/journal.pone.0005724.
Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis.
Sanders N, Franckx H, De Boeck K, Haustraete J, De Smedt S, Demeester J
Thorax. 2006; 61(11):962-8.
PMID: 17071834
PMC: 2121161.
DOI: 10.1136/thx.2006.060814.
Aminoglycoside therapy: current and prospective uses.
Leggett J
Tex Heart Inst J. 1990; 17(4):330-6.
PMID: 15227525
PMC: 324943.
Nebulized antibiotics in cystic fibrosis.
Sermet-Gaudelus I, Le Cocguic Y, Ferroni A, Clairicia M, Barthe J, Brousse V
Paediatr Drugs. 2002; 4(7):455-67.
PMID: 12083973
DOI: 10.2165/00128072-200204070-00004.
P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients.
Sajjan U, Tran L, Sole N, Rovaldi C, Akiyama A, Friden P
Antimicrob Agents Chemother. 2001; 45(12):3437-44.
PMID: 11709321
PMC: 90850.
DOI: 10.1128/AAC.45.12.3437-3444.2001.
Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5.
Rothstein D, Spacciapoli P, Tran L, Xu T, ROBERTS F, Dalla Serra M
Antimicrob Agents Chemother. 2001; 45(5):1367-73.
PMID: 11302797
PMC: 90475.
DOI: 10.1128/AAC.45.5.1367-1373.2001.
Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.
Beringer P, Vinks A, Jelliffe R, Shapiro B
Antimicrob Agents Chemother. 2000; 44(4):809-13.
PMID: 10722474
PMC: 89775.
DOI: 10.1128/AAC.44.4.809-813.2000.
Is prolonged rotavirus infection a common cause of protracted diarrhoea?.
Sood M, Booth I
Arch Dis Child. 1999; 80(4):309-10.
PMID: 10086932
PMC: 1717892.
DOI: 10.1136/adc.80.4.309.
Evidence for using nebulised antibiotics in cystic fibrosis.
Conway S
Arch Dis Child. 1999; 80(4):307-9.
PMID: 10086931
PMC: 1717877.
DOI: 10.1136/adc.80.4.307.
The role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises, more problems.
Zach M
Thorax. 1996; 51(7):750-5.
PMID: 8882085
PMC: 472501.
DOI: 10.1136/thx.51.7.750.
Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection.
Beaulac C, Hawari J, Lagace J
Antimicrob Agents Chemother. 1996; 40(3):665-9.
PMID: 8851590
PMC: 163177.
DOI: 10.1128/AAC.40.3.665.
Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin.
van t Veen A, Mouton J, Gommers D, Kluytmans J, Dekkers P, Lachmann B
Antimicrob Agents Chemother. 1995; 39(2):329-33.
PMID: 7726491
PMC: 162536.
DOI: 10.1128/AAC.39.2.329.